Recently an increasing number of therapies across a wide range of haematological cancers have been investigated in the elderly population. These have included rituximab in patients with chronic lymphocytic leukaemia (CLL) and diffuse large B-Cell lymphoma (DLBCL), dasatinib and imatinib in chronic myeloid leukaemia (CML), dasatinib in de novo Philadelphia positive acute lymphocytic leukaemia (Ph+ ALL) and lenolidamide in multiple myeloma (MM). The results of these trials were presented at ASH 2010.
You can read the full review on ecancer.
Brandcast will be running Europe’s largest ever educational meeting focussed on the elderly blood cancer patient in Rome, March 18-20 2011. 1000 delegates and an leading faculty of experts will gather for the inaugural Blood Cancer in The Elderly European Expert Forum: Ageing and co-morbidity in haematological oncology.